Table 1.

Approved chimeric antigen receptor T-cell (CAR-T) therapies and associated costs

Drug name	Commercial name	Initial publication	N (patients)	Date of FDA approval	Approved indications	Cost (per infusion) US$
Tisagenlecleucel	Kymriah	Maude, S., et al., 2018 [1]	75	*30 Aug. 2017 **1 May 2018	*r/r ALL **r/r DLBCL	*$475,000 **$373,000
Axicabtagene ciloleucel	Yescarta	Neelapu, S., et al., 2017 [2]	101	18 Oct. 2017 5 Mar. 2021	r/r DLBCL r/r Follicular Lymphoma	$373,000
Lisocabtagene maraleucel	Breyanzi	Abramson, J., et al., 2020 [33]	256	5 Feb. 2021	r/r DBLCL and follicular lymphoma grade 3B	$410,300
Brexucabtagene autoleucel	Tecartus	Wang, M., et al., 2020 [36] Shah et al., 2021 [34]	68 71	*24 Jul. 2020 **1 Oct. 2021	*Mantle cell lymphoma **r/r ALL	$373,000
Idecabtagene vicleucel	Abecma	Munshi, N., et al., 2021 [18]	128	26 Mar. 2021	Multiple myeloma	$419,500

r/r relapsed/refractory, ALL acute lymphoblastic leukemia, DLBCL diffuse large B-cell lymphoma

*Denotes date and indication of initial approval

**Denotes date and indication of subsequant approval